Evicenter
MarkdownMedical informationP&T meetings
Ficerafusp alfa (BCA101)

First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab

Last updated
135 sources

Section 5 of 6

Economic information and modeling report

42 evidence topics · 28 sources

Modeling overview

Summary

No budget impact model, cost-effectiveness analysis, or health technology assessment of ficerafusp alfa was found, and no price for it has been published. Bicara states that ficerafusp alfa “may be priced at a significant premium over competitive products if any have been approved by then”, and its presentation describes first-line recurrent or metastatic HPV-negative HNSCC as “a global commercial opportunity of ~$5B+ annually by 2030”. Three published U.S. payer models address first-line comparators. Borse et al. (2022) used a three-state partitioned-survival model over 20 years with 3% annual discounting: pembrolizumab monotherapy was dominant versus the EXTREME regimen in the CPS ≥1 population, and pembrolizumab combination therapy was cost-effective versus EXTREME at $1769/QALY in the overall population. In the Markov model of She et al. (2022), pembrolizumab plus chemotherapy versus cetuximab plus chemotherapy yielded ICERs of $147876.14, $134237.84, and $153660.78 per QALY in the total, CPS ≥1, and CPS ≥20 populations. Ye et al. (2024), using a 15-year three-state partitioned survival model, found the EXTREME regimen cost-effective compared with nivolumab plus ipilimumab at a willingness-to-pay threshold of $150,000/QALY. None of these models includes ficerafusp alfa.

Budget impact model, cost-effectiveness analysis, or health technology assessment of ficerafusp alfa

No evidence found.

Budget impact model

Approach and framework

Budget impact model of ficerafusp alfa: approach and framework

No evidence found.

Good-practice framework for budget impact analysis

Perspective and time frame

Budget impact model of ficerafusp alfa: perspective and time frame

No evidence found.

Epidemiology and eligible population inputs

Budget impact model of ficerafusp alfa: eligible population inputs

No evidence found.

Estimated new cases and deaths in the United States in 2026 by head and neck site
SiteEstimated new cases, both sexesEstimated deaths, both sexes
Oral cavity and pharynx“60,480”“13,150”
Tongue“20,420”“3,560”
Mouth“15,810”“3,340”
Pharynx“21,760”“4,760”
Other oral cavity“2,490”“1,490”
Larynx“12,290”“3,960”
Stage at diagnosis of oral cavity and pharynx cancer
Stage at diagnosisPercent of cases
Localized (confined to primary site)“26%”
Regional (spread to regional lymph nodes)“55%”
Distant (cancer has metastasized)“12%”
Unknown (unstaged)“6%”
Stage at diagnosis of laryngeal cancer
Stage at diagnosisPercent of cases
Localized (confined to primary site)“49%”
Regional (spread to regional lymph nodes)“30%”
Distant (cancer has metastasized)“15%”
Unknown (unstaged)“6%”
Share of oropharyngeal squamous cell carcinoma attributable to HPV in the United States
Measure, oropharynx, 2012 to 2016Value
Reported HPV-associated cancers, average annual number“19,000”View highlighted excerpt for this quote
Attributable to 9vHPV-targeted types, number (%)“12,600 (66)”View highlighted excerpt for this quote
Attributable to other HPV types, number (%)“900 (5)”View highlighted excerpt for this quote
HPV-negative, number (%)“5,500 (29)”View highlighted excerpt for this quote

Cost assumptions

Budget impact model of ficerafusp alfa: cost assumptions

No evidence found.

Ficerafusp alfa price

No evidence found.

United States unit drug, administration, and terminal care costs used in a first-line cost-effectiveness model

Model outcomes

Budget impact model of ficerafusp alfa: model outcomes

No evidence found.

Results

Base case
Budget impact model of ficerafusp alfa: base-case results

No evidence found.

Scenario analyses
Budget impact model of ficerafusp alfa: scenario analyses

No evidence found.

Budget impact model discussion

Summary

Task force good-practice guidance on budget impact analysis lists the key elements of a budget impact analysis as the size of the eligible population, the current and expected treatment mix, the cost of each mix, and changes in condition-related costs, and recommends the perspective of the specific decision maker, data from the decision maker's own population where possible, and presentation as a series of scenario analyses. For ficerafusp alfa, two inputs are not yet available: a price, and efficacy from randomized evidence. Results reported to date come from a nonrandomized, open-label phase 1/1b trial, and Bicara expects an interim analysis of the randomized FORTIFI-HN01 trial in mid-2027.

The population inputs in this report differ by source and are candidates for scenario ranges. The estimated HPV-negative share of recurrent or metastatic disease is 80% in Bicara's Form 10-K; in a U.S. real-world first-line cohort, 60.4% had non-HPV associated disease and 7.0% had unknown HPV status or primary site, and in a U.S. real-world cohort of first-line pembrolizumab recipients, 258 participants (39.9%) were HPV-negative and 155 (24.0%) equivocal or unknown. Bicara states that up to 30% of patients develop a recurrence or metastases after initial treatment for advanced HNSCC; Hanna et al. (2026) state that approximately 50% of those with locally advanced HNSCC have recurrence or metastasis after initial therapy; of 2,207 U.S. participants, 32.7%. Because the pivotal population requires PD-L1 CPS ≥1, testing rates bear on the identifiable population: of 2,207 U.S. participants, 32.7% received PD-L1 testing before first-line therapy and 50.0% were never tested.

On costs, pembrolizumab is given in both arms of FORTIFI-HN01, and ficerafusp alfa is given weekly until disease progression or unacceptable toxicity, while pembrolizumab is given for up to 35 cycles. FORTIFI-FLEX is evaluating a 12-week loading phase of 1500 mg weekly followed by 2250 mg every 3 weeks, which would change the number of administrations if adopted. Bicara states that third-party payers “may refuse to provide coverage and reimbursement for particular drugs when an equivalent generic drug or a less expensive therapy is available.”